查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405755

先進治療藥物市場規模、佔有率、趨勢分析報告：按治療產品類型、地區和細分市場預測，2023-2030 年

Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Product), By Region (North America, Europe, APAC, ROW), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

先進治療藥物市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球先進治療藥物市場規模預計將達到909.8億美元，預測期內複合年成長率為16.8%。

ATMP（先進治療藥品）代表著透過解決根本原因而不是症狀治療來治癒疾病的可能性。因此，ATMP 有助於提供傳統治療方法無法提供的創新益處。預計這些因素將在預測期內推動市場。

繼 Zolgensma、Kymriah 和 Yescarta核准之後，Tecartus 和 Abecma 的突破性核准正在推動該領域取得顯著進展。這些核准正在刺激該行業的投資流入並推動收益成長。主要企業正在採用各種營運模式來加速其產品製造流程。

此外，我們也看到有意進入該行業或擴大現有業務的公司進行了幾起收購。最近的例子包括吉利德生命科學公司收購 Kite Pharma、諾華公司收購 AveXis 以及新基公司收購 Juno Therapeutics。這些收購顯示老牌製藥公司對該市場的興趣日益濃厚。基因療法的收購競爭非常激烈，溢價也很高。

同時，隨著消費者需求的增加，ATMP 製造商擴大將產品製造外包，為受託製造廠商創造了利潤豐厚的機會。因此，一些 CDMO 正在擴大其設施。例如，2021年1月，FUJIFILM Diosynth Biotechnologies投資4000萬美元開發新製程並建立先進療法和病毒載體的製造工廠。

先進治療藥物市場報告亮點

  • Yescarta 和 Kymriah 在日本和歐洲的地域擴張正在鼓勵投資者支持該領域的發展。
  • 最近基因療法的核准大大加速了該領域的臨床試驗。
  • COVID-19 大流行為主要企業投資抗病毒感染疾病的T 細胞研究開拓了新領域。
  • 研究界正在積極評估針對 COVID-19 患者的先進治療的潛力，以幫助市場成長。
  • 由於先進治療的臨床試驗急劇增加，北美在 2022 年佔據了最大的銷售佔有率。
  • 在美國，ATMP 強大的產品線加速了該地區的產生收入。
  • 美國公司將重點從傳統藥物開發轉向 ATMPS，也支持了該地區的成長。
  • 由於以中國為首的新興市場中 ATMP 市場的擴張，亞太地區預計將出現最快的市場複合年成長率。
  • 中國 CDMO 的擴張正在推動區域市場的成長。
  • 主要企業正在採取各種策略措施來維持其市場地位。 ViGeneron GmbH 與 Biogen Inc. 於 2021 年 1 月建立的合作關係是該領域合作的著名例子之一。
  • 兩家公司合作開發以 AAV 為基礎的基因治療產品，用於治療遺傳性眼科疾病。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章先進治療藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 先進治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 先進治療藥物：種類估算及趨勢分析

  • 先進治療藥物市場：要點
  • 先進治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 細胞療法
  • 基因治療
  • 組織工程產品

第5章先進治療藥物市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的先進治療市場：主要市場亮點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第6章競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭分類
    • Spark Therapeutics, Inc.
    • Bluebird Bio, Inc
    • Novartis AG
    • UniQure NV
    • Celgene Corporation
    • Gilead Lifesciences, Inc
    • Kolon TissueGene, Inc
    • JCR Pharmaceuticals Co., Ltd.
    • MEDIPOST
    • Vericel Corporation
    • PHARMICELL Co., Ltd
    • Organogenesis Inc.
Product Code: GVR-3-68038-855-8

Advanced Therapy Medicinal Products Market Growth & Trends:

The global advanced therapy medicinal products market size is expected to reach USD 90.98 billion by 2030, registering a CAGR of 16.8% during the forecast period, according to a new report by Grand View Research, Inc. The ATMPs (Advanced Therapy Medicinal Products) exhibit the potential to cure diseases by addressing their root cause rather than symptomatic treatment. Thus, ATMPs help deliver transformative advantages which are not offered by conventional treatments. These factors are expected to drive the market over the forecast period.

The breakthrough approvals of Tecartus and Abecma post-approval of Zolgensma, Kymriah, and Yescarta have bolstered the exceptional advancements in this space. These approvals have spurred the investment flow in this arena thereby driving revenue growth. Key companies are adopting various operation models to accelerate the product manufacturing process.

Furthermore, the market witnessed several acquisitions by players that intended to enter or expand their existing business in this field. Acquisitions of Kite Pharma by Gilead Life Science, AveXis by Novartis, and Juno Therapeutics by Celgene are some major & recent examples. These acquisitions depict the increasing interest of well-established pharma companies in this market. Increasing competition for gene therapy buyouts can lead to hefty premiums.

On the other hand, with the growing consumer demands, the ATMP manufacturers are outsourcing their product manufacturing thereby creating lucrative opportunities for the contract manufacturing organizations. Thus, several CDMOs have expanded their facilities. For instance, in January 2021, FUJIFILM Diosynth Biotechnologies invested USD 40 million for the establishment of a new process development and manufacturing facility for advanced therapies and viral vectors.

Advanced Therapy Medicinal Products Market Report Highlights:

  • The geographical expansion of Yescarta and Kymriah in Japan and Europe has encouraged the investors to support the development in this space
  • Recent approvals of gene therapies have significantly accelerated the clinical trials in this segment
  • COVID-19 pandemic has opened new areas for key players to invest in T-cell research for viral infections
  • The research community is actively evaluating the potential of advanced therapies in COVID-19 patients, thereby aiding in market growth
  • North America accounted for the largest revenue share in 2022 owing to the exponential rise in clinical trials pertaining to advanced therapies
  • Strong pipeline of ATMPs in the U.S. accelerated revenue generation in the region
  • Also, the shifting focus of U.S.-based companies from conventional drug development to ATMPS is driving regional growth
  • In Asia Pacific, the market is expected to witness the fastest CAGR owing to expanding ATMP landscape in emerging markets such as China at the forefront
  • Expanding business of China-based CDMOs has driven regional market growth
  • Key companies are undertaking various strategic initiatives to maintain their market position. Collaboration between ViGeneron GmbH and Biogen Inc. in January 2021 is one of the notable examples of collaboration in this space
  • The companies collaborated on the development of an AAV-based gene therapy product for the treatment of inherited eye diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapy Type
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapy type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Advanced Therapy Medicinal Products Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Advanced Therapy Medicinal Products Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Advanced Therapy Medicinal Products: Type Estimates & Trend Analysis

  • 4.1. Advanced Therapy Medicinal Products Market: Key Takeaways
  • 4.2. Advanced Therapy Medicinal Products Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Cell Therapy
    • 4.3.1. Cell therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Gene Therapy
    • 4.4.1. Gene therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Tissue Engineered Product
    • 4.5.1. Tissue engineered product market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Advanced Therapy Medicinal Product Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Advanced Therapy Medicinal Products Market by Region: Key Marketplace Takeaway
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
    • 6.2.1. Spark Therapeutics, Inc.
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Bluebird Bio, Inc
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Novartis AG
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. UniQure N.V.
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Celgene Corporation
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Gilead Lifesciences, Inc
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Kolon TissueGene, Inc
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. JCR Pharmaceuticals Co., Ltd.
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. MEDIPOST
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Vericel Corporation
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. PHARMICELL Co., Ltd
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives
    • 6.2.12. Organogenesis Inc.
      • 6.2.12.1. Company overview
      • 6.2.12.2. Financial performance
      • 6.2.12.3. Product benchmarking
      • 6.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 3 North America advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 5 Canada advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 6 Europe advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 7 Europe advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 9 UK advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 10 France advanced therapy medicinal products, by therapy type, 2018 - 2030 (USD Million)
  • Table 11 Italy advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 12 Spain advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 13 Sweden advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 14 Norway advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 15 Denmark advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 18 China advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 19 Japan advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 20 India advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 21 Thailand advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 22 South Korea advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 23 Latin America advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 24 Latin America advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 25 Brazil advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 26 Mexico advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 27 Argentina advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 28 Middle East and Africa advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 30 South Africa advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 31 Saudi Arabia advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 32 UAE advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 33 Kuwait advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Advanced therapy medicinal products: market outlook
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Industry value chain analysis
  • Fig. 13 Advanced therapy medicinal products market driver impact
  • Fig. 14 Advanced therapy medicinal products market restraint impact
  • Fig. 15 Advanced therapy medicinal products market strategic initiatives analysis
  • Fig. 16 Advanced therapy medicinal products market: type movement analysis
  • Fig. 17 Advanced therapy medicinal products market: type outlook and key takeaways
  • Fig. 18 Cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Tissue engineered product market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Global Advanced therapy medicinal products market: regional movement analysis
  • Fig. 22 Global Advanced therapy medicinal products market: regional outlook and key takeaways
  • Fig. 23 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)